FORM D

RECEIVED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| | RM | |
|---|-------|---|
| Г | L IVI | U |

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D. SECTION 4(6), AND/OR **UNIFORM LIMITED OFFERING EXEMPTION**

OMB APPROVAL OMB Number: 3235-0076 Expires: April 30, 2008 Estimated average burden hours per response..... 16.00

| SEC USE ONLY | | | | | |
|---------------|--|--|--|--|--|
| Prefix Serial | | | | | |
| 1 | | | | | |
| DATE RECEIVED | | | | | |
| 1 | | | | | |

| Name of Offering Check if this is an amendment and name has changed, and indicate ch | ange.) |
|--|---|
| Private Placement of BeneChill, Inc. Series B Preferred Stock | |
| Filing Under (Check box(es) that apply): Rule 504 Rule 505 | Rule 506 Section 4(6) |
| Type of Filing: New Filing Amendment | |
| A. BASIC IDENTIFICATION DATA | |
| 1. Enter the information requested about the issuer | |
| Name of Issuer (check if this is an amendment and name has changed, and indicate ch | ange.) |
| BeneChill, Inc. | Telephone Num 07073353 |
| Address of Executive Offices (Number and Street, City, State, Zip Code) | Telephone Ivan |
| 10060 Carroll Canyon Rd, Suite 100, San Diego, CA 92131 | 858-695-8161 |
| Address of Principal Business Operations (Number and Street, City, State, Zip Code) | Telephone Number (Including Area Code) |
| (if different from Executive Offices) | |
| DICD IN CD. | |
| Brief Description of Business | |
| A medical device company developing medical devices for cooling of the body. | |
| • • • • • • • • • • • • • • • • • • • | |
| A medical device company developing medical devices for cooling of the body. | DOACECE |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization | PROCESSE |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization corporation limited partnership, already formed | 2 |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization corporation limited partnership, already formed | ease specify): Sul 3 1 2007 |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization corporation limited partnership, already formed other (ple | 2 |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization corporation limited partnership, already formed other (ple | ease specify): 3 1 2007 THOMSON |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization Corporation limited partnership, already formed other (ple business trust limited partnership, to be formed Actual or Estimated Date of Incorporation or Organization: 0 2 0 6 | THOMSUN Estimate MANCIAL |
| A medical device company developing medical devices for cooling of the body. Type of Business Organization corporation limited partnership, already formed other (ple business trust limited partnership, to be formed Month Year | THOMSON Actual Estimate MANCIAL tion for State: |

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemp-tion, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Fallure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

| A. BASIC IDENTIFICA | ATION DATA | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|
| Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; | | | | | | | | | |
| • Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; | | | | | | | | | |
| • Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and | | | | | | | | | |
| Each general and managing partner of partnership issuers. | | | | | | | | | |
| | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Berman, Michael | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) c/o Apnex Medical, Inc., 5155 East River Road, Suite 413, Fridley, MN 55421 | | | | | | | | | |
| Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Barbut, Denise, M.D. | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 70 East 70 th Street, Apartment 9C, New York, New York 10021 | | | | | | | | | |
| Check Box(es) that Apply: Promoter Beneficial Owner | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Brownell, Robert | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 5980 Horton Street, Suite 390, Emeryville, California 94608 | | | | | | | | | |
| Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Rozenberg, Allan | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 10060 Carroll Canyon Rd, Suite 100, San Diego, CA 92131 | | | | | | | | | |
| Check Box(es) that Apply: Promoter Beneficial Owner | ■ Executive Officer □ Director □ General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Kroloff, Noah | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 369 Lexington Avenue, 17th Floor, New York, New York 10017 | | | | | | | | | |
| Check Box(es) that Apply: Promoter Beneficial Owner | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) Letscher, Thomas A. | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) Plaza VII, Suite 3300, 45 South Seventh Street, Minneapolis, Minnesota 55402 | ? | | | | | | | | |
| Check Box(es) that Apply: Promoter Beneficial Owner | Executive Officer Director General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) MedVenture Associates V, L.P. | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 5980 Horton Street, Suite 390, Emeryville, California 94608 | | | | | | | | | |
| | ■ Executive Officer □ Director □ General and/or Managing Partner | | | | | | | | |
| Full Name (Last name first, if individual) NGN BioMed Opportunity I, L.P. | | | | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) 369 Lexington Avenue, 17th Floor, New York, New York 10017 | | | | | | | | | |

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

| | | | | В. | INFORM | ATION A | BOUT OF | FERING | | | | | |
|---|--|---|--|--|--|--------------|-----------------------|---|--------------|--|---------------------------------------|--|--------|
| 1. Has th | ne issuer so | ld, or does | the issuer i | ntend to se | ll, to non-a | ccredited in | vestors in | this offering | g? | | | Yes | No |
| | | | | | | | | ng under U | _ | | | _ | _ |
| 2. What | is the mini | mum inves | tment that v | | | | | - | | ••••• | | \$ | NA |
| | | | | | | | | | | | Yes | No | |
| 3. Does the offering permit joint ownership of a single unit? | | | | | | | | | | \ <u>⊠</u> | | | |
| sion o to be l name | r similar re isted is an of the brok | emuneration associated er or dealer | ested for each for solicity person or a firmore to for that be | ation of pu gent of a bi han five (5 | rchasers in oker or dea persons to | connection | n with sales | of securities SEC and/ | ies in the o | ffering. If | a person | | |
| Full Name | (Last nam | e first, if ir | ndividual) | | | | | | | . <u>-</u> | <u> </u> | | |
| Business | or Residence | e Address | (Number a | nd Street, C | City, State, 2 | Zip Code) | | | | | · · · · · · · · · · · · · · · · · · · | <u>. </u> | |
| Name of A | Associated | Broker or I | Dealer | · | | . | | | | | | | |
| States in V | Which Pers | on Listed H | las Solicite | d or Intend | s to Solicit | Purchasers | | · . | | | | | |
| | | | individual | States) | | | ****************** | • | ••••••• | | ••••• | | States |
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | (HI) | [ID] | |
| (IL) | [IN] | [lA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] | |
| [MT] | [NE] | [NV] | [NH] | [NJ] | [MM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] | |
| [RI] | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] | |
| Full Name | (Last nam | e first, if in | dividual) | | | | | | | | | | |
| Business o | т Residenc | e Address (| (Number an | d Street, C | ity, State, 2 | Zip Code) | | - | | <u>-</u> | · · · · · · · · · · · · · · · · · · · | | |
| Name of A | ssociated I | Broker or D | Dealer | | | | | | | | | | |
| | | | las Solicited individual S | | | | | | | | | | States |
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | | | | | | States |
| [IL] | [IN] | [IA] | [KS] | [KY] | [LA] | [ME] | [<i>DE</i>] [MD] | [DC] [MA] | [FL] [MI] | [GA] [MN] | [HI] [MS] | [ID] | |
| [MT] | [NE] | [NV] | [NH] | [rn] | [NM] | [NY] | [NC] | [ND] | [MI] | [OK] | | [MO] | |
| [RI] | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [OR] [WY] | [PA] [PR] | |
| Full Name | | | | () | | 11-1 | [] | [] | ["] | [" 1] | ["1] | [1 K] | |
| Business o | r Residence | e Address (| Number an | d Street, C | ity, State, Z | Lip Code) | | | | ······································ | | | |
| Name of A | ssociated H | Broker or D | ealer | | , | | | | | | <u> </u> | | |
| States in W | | | | | | | <u></u> | | | | | | |
| (Check ' | 'All States' | or check i | individual S | States) | •••••• | ••••••• | | ••••••••• | | | ••••• | All: | States |
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] | |
| [IL] | [IN] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] | |
| [MT] | [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] | |
| [RI] | [SC] | (SD) | ITNI | [TX] | IUTI | ſVTI | [VA] | [WA] | ſWVI | rwn | rwvi | ГРР1 | |

[TN] [TX] [UT] [VT] [VA] [WA] [WV]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

| _ | C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND | USE OF PROCEEDS | 3 |
|----|---|------------------------|------------------------|
| 1 | . Enter the aggregate offering price of securities included in this offering and the total amount | t | |
| | already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering. | , | |
| | check this box and indicate in the columns below the amounts of the securities offered for | • | |
| | exchange and already exchanged. | | |
| | | Aggregate | Amount Already |
| | Type of Security | Offering Price | Sold |
| | Debt | \$ 0 | \$ 0 |
| | Equity | \$ 3 512 842 02 | \$ 3,512,842.02 |
| | ☐ Common ☑ Preferred | 5,512,642.02 | \$ 3,312,842.02 |
| | Convertible Securities (including warrants) | ¢ n | ¢Λ |
| | Partnership Interests. | \$ 0 | \$ 0 |
| | Other (Specify) | 30 | \$ 0 |
| | Total | \$ 0 | \$ <u>0</u> |
| | Total | \$ <u>3,512,842.02</u> | \$ <u>3,512,842.02</u> |
| | Answer also in Appendix, Column 3, if filing under ULOE. | | |
| 2. | Enter the number of accredited and non-accredited investors who have purchased securities in | | |
| | this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, | | |
| | indicate the number of persons who have purchased securities and the aggregate dollar amount of | ı | |
| | their purchases on the total lines. Enter "0" if answer is "none" or "zero." | | |
| | t was the same of the same is those of 2010. | | |
| | | M | Aggregate |
| | | Number | Dollar Amount |
| | Accredited Investors | Investors | of Purchases |
| | Non-accredited Investors | 7 | \$ 3,512,842,.02 |
| | Total (for filings under Rule 504 only) | 0 | \$ 0 |
| | Answer also in Annandiv Column A 16 Elian and a LU OF | NA | \$ <u>NA</u> |
| | Answer also in Appendix, Column 4, if filing under ULOE. | | |
| ~ | 10.41 (9): 1 (1 | | |
| ٦. | If this filing is for an offering under Rule 504 or 505, enter the information requested for all | | |
| | securi-ties sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) | | |
| | months prior to the first sale of securities in this offering. Classify securities by type listed in Part | | |
| | C - Question 1. | | |
| | | Type of | Dollar Amount |
| | Type of offering | Security | Sold |
| | Rule 505 | NA | \$ NA |
| | Regulation A | NA NA | \$ NA |
| | Rule 504 | NA NA | \$ NA |
| | Total | NA NA | |
| 4. | a. Furnish a statement of all expenses in connection with the issuance and distribution of the | NA | \$ <u>NA</u> |
| | securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. | | |
| | The information may be given as subject to future contingencies. If the amount of an expenditure | | |
| | is not known, furnish an estimate and check the box to the left of the estimate. | | |
| | Transfer Agent's Fees. | | • • |
| | Printing and Engraving Costs | ····· | \$ 0 |
| | Legal Fees | ····· | \$ 0 |
| | Legal Fees | ····· <u>×</u> | \$ 25,000 |
| | Accounting Fees | 📮 | \$ 0 |
| | Engineering Fees. | | \$ 0 |
| | Sales Commissions (specify finders' fees separately) | | \$ 0 |
| | Other Expenses (identify) | | \$ 0 |
| | Total | 🔯 | \$ 25,000 |
| | | | |

زز

| C. OFFERING PRICE, NUM | IBER OF INVESTORS, EXPENSES AND | USE OF PROC | EEDS |
|---|--|--|--|
| b. Enter the difference between the aggregate offetion 1 and total expenses furnished in response to "adjusted gross proceeds to the issuer." 5. Indicate below the amount of the adjusted gross pused for each of the purposes shown. If the amoestimate and check the box to the left of the estimate adjusted gross proceeds to the issuer set forth in | Part C - Question 4.a. This difference is the surface of the issuer used or proposed to built for any purpose is not known, furnish atte. The total of the nayments listed must equi | he be | \$ <u>3,487,842.02</u> |
| Salaries and fees | | Payments Officers Directors, Affiliate | & Payments to Others |
| Purchase of real estate | ····· | \$ <u>0</u> | 5 0 |
| Purchase, rental or leasing and installation of n | nachinery and equipment | \$ <u>0</u> | \$0 |
| Construction or leasing of plant buildings and | facilities | \$ 0 | 5 0 |
| Acquisition of other businesses (including the offering that may be used in exchange for the a issuer pursuant to a merger) | ssets or securities of another | \$ <u>0</u> | []\$ 0 |
| Repayment of indebtedness | | \$ 0 | |
| Working capital | | \$ 0 | D\$0 |
| Other (specify): Product Development, Anima | l Testing, Clinical Trials | \$ 0 | \$ 2,987,842.02 |
| General and Administrative | | \$ 0 | \$500,000.00 |
| Column Totals | | \$ 0 | \$ 3,487,842.02 |
| Total Payments Listed (column totals added) | | . 🛛 | \$3,487,842.02 |
| | | | |
| | D. FEDERAL SIGNATURE | | |
| The issuer has duly caused this notice to be signed by the signature constitutes an undertaking by the issuer to furnished by the issuer to any non-accredite | nish to the U.S. Securities and Exchange Cor | ทางเรรโกก บากกา พา | nder Rule 505, the following ritten re-quest of its staff, the |
| Issuer (Print or Type) | Signature | | Date |
| BeneChill, Inc. | | | |
| Name of Signer (Print or Type) | Title of Signer (Print or Type) | \sim | July / 7, 2007 |
| Allan Rozenberg | | | |
| · · · · · · · · · · · · · · · · · · · | Chief Operating Officer | | |

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

| | E. STATE SIGNATURE | | - |
|----|--|-----|-------------|
| 1. | Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule? | Yes | No |
| | or such fule? | | \boxtimes |
| | See Appendix, Column 5, for state response. | | |

- The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

| Issuer (Print or Type) | Signature | Date |
|------------------------|-------------------------|---------------|
| BeneChill, Inc. | Cen | July 17, 2007 |
| Name (Print or Type) | Title (Print or Type) | |
| Allan Rozenberg | Chief Operating Officer | |

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

| 1 | | 2 | 3 | Type of investor and amount purchased in State (Part C-Item 2) | | | 5 Disqualification | | |
|-------|----------|--|--|--|----------------|--------------|---|--------------|-------------------------|
| | to non-a | d to sell accredite rs in State 3-Item 1) | e Offered in state | | | | under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item I) | | |
| State | Yes | No | | Number of Accredited Amount Investors Number of Number of Non-Accredited Investors | | Yes | No | | |
| AL | | <u> </u> | | | | | | | - |
| AK | | L | | | <u> </u> | | | | |
| AZ | | | | | | | | | |
| AR | | | | | <u> </u> | | | | - |
| CA | | X | Series B Preferred Stock \$1,512,841.70 | 3 | \$1,512,841.70 | | | | Х |
| СО | | | | | ļ | | | <u> </u> | |
| CT | | | | | | | | <u> </u> | |
| DE | | | | | | - | | | |
| DC | | | | | | | | | |
| FL | | - | | | | | | | |
| GA | | | | | | | | | |
| Hi | | | | _ | | | | <u> </u> | |
| ID | | | | | - | | | | |
| IL | | | | | | | | | |
| ĪΝ | | | | | - | | | - | |
| IA | | - | | | | | <u> </u> | | |
| KS | | | | | - | | | | |
| KY | | | | | | | | _ | |
| LA | | | | | | | | | |
| ME | | | | | | | | | ——- |
| MD | | | | | - | | | + | |
| MA | | _ | | | | | | | |
| MI | | - | | | | | - | | |
| MN | | X | Series B Preferred Stock \$49,999.66 | 1 | \$49,999.66 | | - | | $\overline{\mathbf{x}}$ |
| MS | | | | | | <u></u> | | | |
| МО | | | | | | | | | |

| Check Box(es) that Apply: | Promoter | Beneficial Owner | Executive Officer | ☐ Director | General and/or Managing Partner |
|---|---|--|-------------------|------------|---------------------------------|
| Full Name (Last name first, i NGN BioMed Opportunity I | GmbH & Co. Betei | - • | | | |
| Business or Residence Addre 369 Lexington Avenue, 17th | ess (Number and Str Floor, New York, 1 | reet, City, State, Zip Code) New York 10017 | | | |

END